(4-Methoxyphenyl)[4-(4-methoxyphenyl)piperazin-1-yl]methanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (4-Methoxyphenyl)[4-(4-methoxyphenyl)piperazin-1-yl]methanone
• 英文别名: (4-methoxyphenyl)-[4-(4-methoxyphenyl)piperazin-1-yl]methanone
• 化学式: C₁₉H₂₂N₂O₃
• 分子量: 326.395
• InChiKey: AFHKFTNYWWGHCB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  42
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE<br/>[FR] AGONISTES SÉLECTIFS DU RÉCEPTEUR DE LA DOPAMINE D3 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：US HEALTH

  公开号：WO2017181004A1

  公开（公告）日：2017-10-19

  The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.

  公式(I)的化合物或其药用可接受的盐的披露。变量W、R1、R2、R3和R4在披露中有定义。该披露提供了公式(I)的化合物或盐，以及药用可接受的载体。该披露还提供了治疗帕金森病和相关综合征、特别是因治疗帕金森病使用L-DOPA而引起的运动障碍、神经退行性疾病如阿尔茨海默病和痴呆症、亨廷顿病、不安腿综合征、躁郁症和抑郁症、精神分裂症、认知功能障碍或物质使用障碍的方法，包括向患者施用公式I的化合物或其盐。该披露提供了联合治疗方法，其中将公式(I)的化合物与一个或多个额外活性剂一起施用给患者。
• EP3442955B1
  申请人：——

  公开号：EP3442955B1

  公开（公告）日：2021-09-29
• SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human

  公开号：US20210323941A1

  公开（公告）日：2021-10-21

  The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R 1 , R 2 , R 3 , and R 4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.